Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Endocrinol
Main Authors: Schneider, T. C., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H., van Wezel, T., van Eijk, R., Morreau, H., Guchelaar, H. J., Kapiteijn, E.
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2015
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532868/
https://ncbi.nlm.nih.gov/pubmed/26294908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/348124
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados